1. Home
  2. TRDA vs XPER Comparison

TRDA vs XPER Comparison

Compare TRDA & XPER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$6.78

Market Cap

275.3M

Sector

Health Care

ML Signal

HOLD

Logo Xperi Inc.

XPER

Xperi Inc.

HOLD

Current Price

$5.50

Market Cap

282.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
XPER
Founded
2016
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
275.3M
282.9M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
TRDA
XPER
Price
$6.78
$5.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$21.00
$11.67
AVG Volume (30 Days)
265.1K
373.4K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,421,000.00
$448,105,000.00
Revenue This Year
$39.97
$4.03
Revenue Next Year
$50.80
$8.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.08
$5.07
52 Week High
$16.45
$8.75

Technical Indicators

Market Signals
Indicator
TRDA
XPER
Relative Strength Index (RSI) 45.46 29.18
Support Level $6.76 $5.07
Resistance Level $7.89 $5.74
Average True Range (ATR) 0.44 0.14
MACD -0.04 0.01
Stochastic Oscillator 34.75 11.01

Price Performance

Historical Comparison
TRDA
XPER

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About XPER Xperi Inc.

Xperi Inc is a media and entertainment technology company. Its technologies are integrated into consumer devices, connected cars, and a variety of media platforms globally, enabling audiences to connect with entertainment content in a more intelligent, immersive, and personal way. As its audiences engage with content on the platform, the company operates a cross-screen advertising solution that enables brands to reach millions of engaged consumers across rapidly expanding digital entertainment ecosystem. It operates in one reportable business segment and group its revenue into four categories: Pay-TV, Consumer Electronics, Connected Car and Media Platform. Geographically it operates in U.S. and Canada, Asia Pacific, Europe, Middle East and Africa, and Other countries.

Share on Social Networks: